About ArcheNova
Accelerating the Future of
Biopharmaceutical Innovation
ArcheNova is a global biopharmaceutical value creation platform. We integrate breakthrough technologies, accelerate clinical development, and enable global commercialization to unlock the scientific, clinical, and commercial potential of innovative biopharmaceutical assets.
Our Mission
Transform scientific innovation into enduring therapeutic value.
Our Vision
Redefining the Future of Biopharmaceutical Innovation.
End-End Value Creation
Our Biopharmaceutical
Value Creation Model
Discover High-Value Assets
Identify and develop promising biopharmaceutical assets with strong clinical and commercial potential.
Rebuild Assets
Transform innovative assets into high-value therapies through strategic development and optimization.
Clinical Development
Streamline clinical development with integrated R&D, regulatory, and quality expertise.
Global Commercialization
Bring innovative therapies to global markets through partnerships, licensing, and commercialization.
Core Technology
MSC-derived Exosome Platform
ArcheNova's wholly owned subsidiary is dedicated to the development, clinical translation, and commercialization of MSC-derived exosome therapeutics.
Immortalized MSC Platform
Our proprietary Immortalized MSC Platform provides a stable, renewable, and standardized cell source for the consistent production of clinical-grade exosomes.
Therapeutic Focus
Regenerative Medicine
Inflammatory Diseases
Ophthalmology
Orthopaedics
Neurodegenerative Diseases
- Integrated platform
- Strong scientific foundation
- Global partnership